PNC-27 peptide is also known as:
- HDM2-binding peptide
- Membrane-active peptide
- Tumor-penetrating peptide
- Penetratin-p53 peptide
- OncoSec Medical Systems 102
- OSI-102
PNC-27 was initially developed by a team of researchers at the University of Pennsylvania and was later licensed to OncoSec Medical Systems. OncoSec Medical Systems is currently developing PNC-27 for the treatment of a variety of cancers, including breast cancer, lung cancer, melanoma, and prostate cancer.
PNC-27 is a synthetic peptide that is thought to work by binding to a protein called HDM2. HDM2 is a negative regulator of the p53 tumor suppressor protein. p53 is a key protein that helps to control cell growth and division. When HDM2 binds to p53, it inactivates it. This can allow cancer cells to grow and divide uncontrollably.
PNC-27 is thought to compete with HDM2 for binding to p53. This can free up p53 to perform its tumor suppressor functions. One of the main functions of p53 is to induce apoptosis, or programmed cell death, in damaged or cancerous cells.
In addition to inducing apoptosis, PNC-27 may also kill cancer cells by other mechanisms, such as disrupting the blood supply to the tumor or activating the immune system to attack the tumor.
PNC-27 is currently in clinical trials for the treatment of a variety of cancers. The results of these clinical trials so far have been promising. For example, one clinical trial of PNC-27 in patients with advanced breast cancer found that PNC-27 was effective in reducing tumor size and improving overall survival.
PNC-27 is a promising new cancer treatment that has the potential to make a significant impact on the lives of cancer patients. More research is needed, but PNC-27 has the potential to be a valuable new tool in the fight against cancer.
